alexa Propranolol In Angiosarcoma: First Major Advance In Decades | 69231
ISSN: 2161-1459

Journal of Clinical & Experimental Pharmacology
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

8th World Congress on Pharmacology and Toxicology
July 24-25, 2017 Melbourne, Australia

Shripad Banavali
Tata Memorial Hospital, India
Keynote: Clin Exp Pharmacol
DOI: 10.4172/2161-1459-C1-018
Abstract
Background: Angiosarcomasare rare malignant tumors of vascular origin that represent a therapeutic challenge. In recent times,the combination of metronomic therapies and drug repositioning has been proposed as an effective alternative for cancer patients. We tried to explore such therapies in difficult to treat, metastatic/recurrent, angiosarcoma patients. Methods: In vitro experiments with transformed endothelial cells were used to identify synergistic interactions between betablocker propranolol and various chemotherapeutic drugs. This led to exploration of pilot treatment protocol containing oral propranolol along with metronomic therapies. Treatment was delivered for one year followed by oral maintenance till disease progression. Results: Our data shows that all angiosarcoma tumors express ADRB1 and /or ADRB2 adrenergic receptor genes. Propranolol strongly synergized with micro-tubular-targeting agent vinblastine, but only showed additive or slight antagonism with drugs routinely used for the treatment of angiosarcoma viz. doxorubicin and paclitaxel. Based on this data a combination treatment was designed using oral propranolol / weekly injectable metronomic vinblastineand methotrexate, given for up-to 1 year, followed by oral maintenance with propranolol/ etoposide/ cyclophosphamide. This regimen gave us 100% response rate in the 14 patients treated with median PFS of 10.6 months and OS of 17.8 months. The toxicity was acceptable with 3 patients having grade 3 or 4 toxicity (1 Thrombocytopenia, 1 diarrhea, 1 febrile neutropenia). Conclusion: Our data provides strong rationale for the combination of metronomic chemotherapy and propranolol in angiosarcomawhich warrants additional studies. It also illustrates the potentialof metronomics to generate innovative, yet inexpensive, targeted therapies for both high-income and low/middle income countries.
Biography

Shripad Banavali has done his MD in Internal Medicine & Adult Oncology training in India, followed by Board Certification in Pediatrics and Fellowship in Pediatric- Hematology-Oncology in USA. Presently he heads the Department of Medical & Pediatric Oncology at the Tata Memorial Hospital, Mumbai; India. His area of research is Drug Repurposing and development of low-cost, Metronomic Protocols for the treatment of various cancers. He has more than 170 publications. He is recipient of 5 Orations and has received the International “Barton Kamen Prize” in recognition of Research on Metronomics in Childhood cancers.

Email: [email protected]

image PDF   |   image HTML
 

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version